Brick & Kyle Associates’s AstraZeneca AZN Stock Holding History

Brick & Kyle Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-399	Closed	-$25K	–	118
2017 Q1	$25K	Hold	399	–	–	0.02%	254
2016 Q4	$22K	Hold	399	–	–	0.02%	265
2016 Q3	$26K	Hold	399	–	–	0.02%	239
2016 Q2	$24K	Hold	399	–	–	0.02%	243
2016 Q1	$22K	Hold	399	–	–	0.02%	241
2015 Q4	$27K	Hold	399	–	–	0.02%	216
2015 Q3	$25K	Hold	399	–	–	0.02%	227
2015 Q2	$25K	Hold	399	–	–	0.02%	246
2015 Q1	$27K	Hold	399	–	–	0.02%	240
2014 Q4	$28K	Buy	+399	New	+$28.6K	0.02%	223

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Brick & Kyle Associates's AZN Position: Q2 2017 in Review

Brick & Kyle Associates sold out of AstraZeneca (AZN) in Q2 2017, closing a stake of 399 shares — an estimated $25K sold.

Brick & Kyle Associates first reported a position in AZN in Q4 2014 and held it in 10 quarters. The position peaked at $28K in Q4 2014. 466 funds tracked by Wall St. Rank hold AZN as of Q2 2017.

Brick & Kyle Associates reported no remaining AstraZeneca position as of Q2 2017 after selling out during the quarter.
Brick & Kyle Associates sold 399 AstraZeneca shares in Q2 2017, an estimated $25K.
Brick & Kyle Associates first reported a position in AstraZeneca in Q4 2014 and held it in 10 quarters.
Brick & Kyle Associates's AstraZeneca position peaked at $28K in Q4 2014.
466 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2017.

Based on Brick & Kyle Associates's 13F filing for Q2 2017, filed 14 Aug 2017.